Please sign in to follow a disease.
Tauopathy
MONDO:0005574Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (tau proteins) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with alzheimer disease; dementia; parkinsonian disorders; progressive supranuclear palsy (supranuclear palsy, progressive); and corticobasal degeneration.
1193 clinical trials for this condition and its sub-types, 24 tagged with Tauopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Tauopathy
-
Alzheimer disease 1,187 trials
5 sub-types
- Familial Alzheimer disease 13 trials · 55 incl. sub-types Sub-types →
- Alzheimer disease 16 1 trial
- Alzheimer disease 17 1 trial
- Alzheimer disease 18 1 trial
- Alzheimer disease 19 1 trial
-
Argyrophilic grain disease 0 trials
Most studied deeper sub-types
-
Alzheimer's drug ALZ-801 tested Long-Term in High-Risk group
Disease control Stopped earlyThis study looked at the long-term safety and effects of ALZ-801, a tablet taken twice daily, in 163 people with early Alzheimer's disease who have the APOE4/4 gene. Participants had already completed a previous phase 3 study. The goal was to see if the drug could slow cognitive …
Phase 3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control Stopped earlyThis early-stage study tested a new drug, ADEL-Y01, in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.
Phase 1 • Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control Stopped earlyThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC